Does Medicare Cover Wegovy or Zepbound? The $50 Bridge

Medicare's GLP-1 Bridge gives eligible people with Part D drug coverage access to certain weight-management medicines for $50 per month. It began in July 2026 and is scheduled to continue through December 2027. It is a temporary demonstration with specific clinical criteria, not universal GLP-1 coverage.¹

Which medicines and devices qualify?

Medicare lists Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen. Single-dose Zepbound pens and vials are excluded from this program.² Ask the prescriber and pharmacy to verify the delivery format before they process the prescription; “Zepbound” alone is not sufficiently specific.

You can participate through eligible standalone Part D or Medicare Advantage drug coverage. The decision depends on the coverage and clinical rules, rather than the Medicare Advantage label alone.²

Who is eligible?

Medicare's published criteria require adults starting GLP-1 therapy to have one of these combinations:

People already receiving GLP-1 coverage through Part D are excluded. Medicare also directs people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease toward the ordinary plan coverage route where applicable.² These are coverage criteria; your clinician must still assess whether treatment is appropriate for you.

Bring records of your pretreatment weight, diagnoses, medicines, and prior GLP-1 coverage to the appointment. If you have already lost weight on treatment, ask how the initiation criteria apply to your situation rather than assuming today's BMI answers the entire question.

How the authorization works

Your clinician sends a prescription to the pharmacy and completes the authorization process when requested. They must certify that treatment accompanies a lifestyle program focused on diet and exercise. Medicare says an approved authorization remains valid through December 2027 for refills and dose changes unless you change GLP-1 drugs.²

A pharmacy rejection is not always a clinical denial. Ask whether it reflects the product format, missing authorization, an eligibility mismatch, or a processing problem. Keep the decision letter and ask who must supply the missing information. Do not pay a new membership fee solely because a service promises to “unlock” Medicare coverage.

Why the $50 does not behave like a usual Part D copay

CMS administers the Bridge outside the normal Part D benefit structure. The copay does not count toward the Part D deductible or out-of-pocket threshold, and the Low-Income Subsidy does not reduce it.³ Twelve monthly fills at $50 total $600 before unrelated care costs. Reaching your regular Part D limit does not make these Bridge fills free.

Compare that with the actual copay on any medication your existing plan covers for another approved indication. A smaller advertised figure does not justify disrupting a covered treatment without checking both routes.

What happens after December 2027?

The current end date is a planning limit, not a promise of a successor. Ask the treating practice how it will handle future coverage changes. Avoid a long prepaid service commitment based on an assumed extension.

Medicaid has different state and plan rules. Medicare's national Bridge eligibility does not prove that a Medicaid plan will cover the same drug, and a manufacturer commercial savings card is another distinct program.

Compare care, not only fulfillment

Read NovoCare Pharmacy's review and LillyDirect Foundayo's review to understand manufacturer fulfillment. Ro's review covers a separate prescribing service. Ask each about Medicare participation, the care fee, and authorization responsibilities before paying. The without-insurance board can help price a backup option, but it does not determine Medicare eligibility.

For the products themselves, see Zepbound devices and Foundayo prices.